Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...

Please provide your email address to receive an email when new articles are posted on . Treatment with sodium-glucose cotransporter-2 inhibitors for type 2 diabetes may reduce the risk for rheumatoid ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

The use of SGLT2 inhibitors was not associated with a clear increase in overall UTI risk among patients with RA and diabetes.

Please provide your email address to receive an email when new articles are posted on . SGLT2 and GLP-1 agents were linked to lower risk of kidney-related outcomes for adults with type 2 diabetes and ...

Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...

Preoperative use of SGLT2 inhibitors among patients with type 2 diabetes undergoing emergency surgery was not associated with ...

HOUSTON -- SGLT2 inhibitors may hold a benefit for a wider pool of patients with chronic kidney disease (CKD) than previously thought, a pair of meta-analyses indicated. SGLT2 inhibitors helped to ...

GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...

BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among patients with pulmonary arterial hypertension (PAH), according to an ...